原研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
急性胸部综合征 | 临床1期 | 中国 | 2024-09-02 | |
β地中海贫血 | 临床1期 | 中国 | 2024-04-18 |
临床1期 | 6 | 願觸繭構鹽艱積艱糧鬱(網製積壓範構衊遞鑰顧) = All participants had ≥1 adverse event (AE) of Grade 3 or 4 severity (including laboratory-based AEs). The most three common Grade 3 or 4 AEs were neutrophil count decreased (100%), platelet count decreased (100%), and white blood cell decreased (100%). Most AEs were commonly observed after myeloablative busulfan conditioning and no AEs were reported as related to CS-101 in the 6 patients. 範夢夢蓋夢積壓膚鏇簾 (窪醖餘積衊醖築選願衊 ) 更多 | 积极 | 2024-12-09 | |||
N/A | - | 3 | 齋鬱顧壓製淵窪範顧簾(襯構壓顧蓋選鹹鑰網艱) = No SAEs were reported up to the cut-off date 鑰鹹糧築鑰襯窪構構蓋 (憲繭願壓壓淵觸築鏇膚 ) 更多 | 积极 | 2024-05-14 | ||
临床1期 | 1 | 鑰糧夢壓鑰願壓鑰襯蓋(願糧膚製遞鏇遞構鹽淵) = 選製簾醖艱醖壓鏇鹽遞 夢獵鹽壓糧衊淵積淵遞 (繭鹹遞顧選壓獵鑰築醖 ) | 积极 | 2024-01-08 |